Breath tests

Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc.

Retrieved on: 
Friday, July 23, 2021

With this acquisition, Meridian will assume the customer relationships in North America to supply BreathTek, a urea breath test for the detection of Helicobacter pylori.

Key Points: 
  • With this acquisition, Meridian will assume the customer relationships in North America to supply BreathTek, a urea breath test for the detection of Helicobacter pylori.
  • We look forward to supporting Otsukas customers with the gastrointestinal expertise and world class customer service Meridian is known for.
  • Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.
  • Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products.

Breath Analyzer Markets: Alcohol Detection, Drug Abuse Detection, & Medical Application - Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021

The "Breath Analyzer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Breath Analyzer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The breath analyzer is a hand-held medical device that is primarily used for onsite detection of alcohol or drug content in the blood through the exhaled breath.
  • Key Questions Answered in This Report:
    How has the global breath analyzer market performed so far and how will it perform in the coming years?
  • What is the structure of the global breath analyzer market and who are the key players?

World Small Intestinal Bacterial Overgrowth Diagnostics Market Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 1, 2021

The "Small Intestinal Bacterial Overgrowth Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Diagnosis; Type, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Small Intestinal Bacterial Overgrowth Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Diagnosis; Type, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The global SIBO diagnostics market is expected to reach US$ 194,604.51 thousand by 2028 from US$ 138,324.23 thousand in 2020.
  • Hydrogen breath tests for carbohydrate malabsorption, and lactulose and glucose hydrogen breath tests for bacterial growth are the widely used breath tests.
  • Based on diagnosis, the SIBO diagnostics market is segmented into breath testing, small intestine aspirate and fluid culture test, blood test, and others.

Lumen Metabolic Health Device Now Peer-reviewed

Retrieved on: 
Monday, May 17, 2021

View the full release here: https://www.businesswire.com/news/home/20210517005774/en/\nDeveloped through years of scientific testing and validation, Lumen is the first handheld, portable device and app that measures your metabolism in real-time with just your breath.\nThe study compares the metabolic fuel measurement capabilities of the Lumen device to the gold standard measurement of metabolic carts.

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210517005774/en/\nDeveloped through years of scientific testing and validation, Lumen is the first handheld, portable device and app that measures your metabolism in real-time with just your breath.\nThe study compares the metabolic fuel measurement capabilities of the Lumen device to the gold standard measurement of metabolic carts.
  • Metabolic carts are known to be costly and only available to the public in laboratory settings.\nLumen has made metabolic testing accessible as the only handheld device available to measure your metabolism from home via the CO2 exhaled from the breath.\n"We are thrilled the scientific community recognizes Lumen\'s ability to measure metabolic fuel utilization as effectively as the metabolic cart.
  • The Lumen device measures metabolism in a single breath, in less than a minute, which previously was only possible through an hour-long lab test.
  • Lumen is headquartered in Israel, with offices in the United States.\nThe Lumen device is available at Lumen.me , currently priced at $299.\nThe device comes equipped with a travel case, charging dock, USB-C Cable, and Premium Customer Support.

Global Helicobacter Pylori Tests (In Vitro Diagnostics) Market Analysis and Forecast Report 2020-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 26, 2021

b'The "Helicobacter Pylori Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com\'s offering.\nHelicobacter Pylori Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.\nThe model discusses in detail the impact of COVID-19 on Helicobacter Pylori Tests market for the year 2020 and beyond.

Key Points: 
  • b'The "Helicobacter Pylori Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com\'s offering.\nHelicobacter Pylori Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.\nThe model discusses in detail the impact of COVID-19 on Helicobacter Pylori Tests market for the year 2020 and beyond.
  • It gets transmitted from mother-to-child in developed countries, but horizontal transmission is not observed in developed countries due to better sanitary conditions.\nThe prevalence is lower in developed nations with a prevalence rate of 15.5% when compared to the developing countries having a prevalence rate of 93.6%.
  • The main causes for the high prevalence of infection are poverty enhanced level of transmission due to malnutrition, poor hygiene and unaffordable heath care indicating low socioeconomic status in regions like Asia, South America and Africa.
  • Helicobacter Pylori Tests is segmented into Helicobacter pylori Breath Test, Helicobacter pylori Feces Test, Helicobacter pylori IHC Test, Helicobacter pylori Serology EIA Test, Helicobacter Pylori Point of Care (POC) Tests and Helicobacter Pylori Other Tests.\nCMO executives who must have deep understanding of the Helicobacter Pylori Tests market place to make strategic planning and investment decisions.\nSourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.\nPrivate equity investors that need a deeper understanding of the market to identify and value potential investment targets.\nUnderstand the impact of COVID-19 on Helicobacter Pylori Tests market.\nDevelop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.\nDevelop business strategies by understanding the trends shaping and driving Helicobacter Pylori Tests market.\nDrive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Helicobacter Pylori Tests market in the future.\nFormulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.\nIdentify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.\nTrack device sales in the global and country-specific Helicobacter Pylori Tests market from 2015-2030.\nOrganize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.\n'

DeepVerge PLC: Microtox® BT Evaluation of SARS-CoV-2 from breath test with Clinical Samples

Retrieved on: 
Wednesday, March 17, 2021

The breath samples detected binding on the nano-optofluidic chip with a secondary antibody to the Spike Protein which was initially selected for the isolated spike protein work.

Key Points: 
  • The breath samples detected binding on the nano-optofluidic chip with a secondary antibody to the Spike Protein which was initially selected for the isolated spike protein work.
  • Further data is required to confirm the same high sensitivity and specificity is achieved on breath test clinical trials which are underway.
  • Gerard Brandon CEO of DeepVerge plc commented:
    "DeepVerge scientists have transformed its AI based water contamination detection system, developed over five years for e.coli, into the breath condensate MicrotoxBT unit.
  • "The requirement for the UK Target Product Profile ("TPP") Rapid Breath Test requires 150 confirmed positive samples and 250 confirmed negative samples.

Study Finds MediPines' Breakthrough Non-invasive Gas Exchange Method Highly Precise: Ideal for Covid Response

Retrieved on: 
Monday, February 1, 2021

Using the MediPines AGM100 , a respiratory medical device,researchers were able to demonstrate that the new breath-based measurement of gas exchange efficiency has very low variability and is highly correlated with established blood-sampling methods.

Key Points: 
  • Using the MediPines AGM100 , a respiratory medical device,researchers were able to demonstrate that the new breath-based measurement of gas exchange efficiency has very low variability and is highly correlated with established blood-sampling methods.
  • A breath-based gas exchange analysis using the AGM100 is easy to obtain for both practitioner and patient.
  • The gas exchange analysis provided by the AGM100 requires the patient to simply breath into a mouthpiece and can be completed within two minutes.
  • MediPines Corporation, based inCalifornia, is a market leader in respiratory assessment and monitoring of pulmonary gas exchange.

Medivolve Announces Investment Into Marvel Diagnostics and Its Non-Invasive Exhaled Breath Diagnostic Technology

Retrieved on: 
Thursday, January 28, 2021

It is a simple matter of extracting the exhaled breath condensate from the collection zone and shipping it off for diagnostic testing.

Key Points: 
  • It is a simple matter of extracting the exhaled breath condensate from the collection zone and shipping it off for diagnostic testing.
  • Medivolve will make an initial investment of US$165,000 within 30 days to acquire approximately 6.6% of Marvel Diagnostics.
  • Medivolve will make a second investment of US$165,000 within 60 days to acquire an additional 6.6% of Marvel Diagnostics.
  • As part of the investment, Medivolve will appoint a director to the board of directors of Marvel Diagnostics.

Breathonix announces 60 secs, on-site, non-intrusive rapid breath test for COVID-19

Retrieved on: 
Thursday, October 29, 2020

The principle of the breath test is fundamentally different from current PCR (Polymerase Chain Reaction) tests.

Key Points: 
  • The principle of the breath test is fundamentally different from current PCR (Polymerase Chain Reaction) tests.
  • The platform detects and processes Volatile Organic Compounds (VOCs) in human breath to determine if a person is infected with the coronavirus.
  • "With the advantages of 60 seconds in-situ test of COVID-19, the Breathonix system could potentially be used for mass screening in areas of high human traffic," said A/Prof Neo Kok Beng, Chairman of Breathonix.
  • If assessed to be suitable, the Breathonix breath analysis platform could be deployed in airports, sea-ports and transportation hubs.

Gemelli Biotech Launches Novel Breath Test Measuring Hydrogen, Methane and Hydrogen Sulfide

Retrieved on: 
Tuesday, October 27, 2020

Los Angeles- and Raleigh-based Gemelli Biotech announced the launch of a novel breath test called trio-smart that provides a more complete fermented gas profile of a patients microbiome by measuring levels of hydrogen, methane, and hydrogen sulfide after the consumption of a sugar substance (lactulose or glucose).

Key Points: 
  • Los Angeles- and Raleigh-based Gemelli Biotech announced the launch of a novel breath test called trio-smart that provides a more complete fermented gas profile of a patients microbiome by measuring levels of hydrogen, methane, and hydrogen sulfide after the consumption of a sugar substance (lactulose or glucose).
  • As a result, many patients with serious GI symptoms appear normal on hydrogen and methane breath tests.
  • An estimated 25% of patients who appear normal on hydrogen and methane tests could have elevated hydrogen sulfide levels and associated GI complications, says Dr. Mark Pimentel, executive director of MAST.
  • Competitive Hydrogen Gas Utilization by Methane- and Hydrogen Sulfide-Producing Microorganisms and Associated Symptoms: Results of a Novel 4-Gas Breath Test Machine.